news aktuell GmbHnews aktuell GmbH

Bullfinch AG: Bullfinch AG and Aquila Capital launch Joint Investment Vehicle for energy-efficient assets

4.5.2021 16:22:12 CEST | news aktuell GmbH | Press release

Share

(Frankfurt, Germany): Aquila Capital and bullfinch are pleased to announce the launch of a strategic joint investment vehicle intended to invest in energy efficiency assets across Europe. By combining Aquila Capital’s leading investment experience in real assets and renewable energy, with bullfinch’s unique expertise in decentralized renewable projects and next-gen technology platform, the partnership intends to make an immediate impact in the renewable investment landscape.

With more than EUR 25 trillion to be invested in upgrading real estate assets across Europe to achieve climate goals, decentralized green infrastructure projects play an increasingly critical role in fighting climate change. The joint investment vehicle aims to become a relevant pure player in energy efficiency, targeting an investment of more than EUR 200 million in the next two years.

Aquila and bullfinch’s initiative will support the fast expansion of digital smart metering through financing, asset acquisition, and operations. Ultimately, Aquila and bullfinch are working together to realize the common vision of a world entirely powered by clean energy.

 

Bullfinch AG

Bullfinch AG, based in Frankfurt am Main, was founded in 2019 by CEO Robin Haack. The company is committed to a world powered by renewable energy: The Clean-Energy-as-a-Service technology platform enables the bundling, financing, standardization and management of sustainable building and facility infrastructure to make this vision a reality. Bullfinch's solutions span four verticals: Power Generation, Clean Mobility, Energy Storage and Smart Buildings. Through partnerships with institutional investors and innovative energy hardware providers, they bridge the gap between capital and opportunity, enabling the accelerated global transition to clean energy.

Contacts

Bullfinch AG
Lucas Neurauter c/o BETTERTRUST GmbH, Luisenstraße 40, 10117 Berlin
Tel: (+49) 30 / 340 60 10 - 93, Mobil: (+49) 0176 / 619 111 76,
l.neurauter@bettertrust.de

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:54:06 CET | Press release

Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands2.3.2026 10:39:09 CET | Press release

Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 brands across six therapeutic areas and >60 markets.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye